Shao Wei-Li, serving as President of Omada Health, Inc. (NASDAQ:OMDA), completed a transaction involving the sale of 4,037 shares of the company's common stock on June 12, 2026. The aggregate value of this divestment was approximately $69,600. The execution of these shares occurred at prices fluctuating between $17.10 and $17.54 per share. A reported price of $17.2407 per share represents a weighted average of the transaction costs.
This specific sale was facilitated through a pre-arranged 10b5-1 trading plan, which Mr. Shao initiated on March 13, 2026. The recent filing serves as an amendment to a prior disclosure, intended to correct an administrative error made by the broker that had previously overstated the volume of shares sold. Following this adjustment, Mr. Shao maintains direct ownership of 316,790 shares of Omada Health common stock.
Omada Health, a digital health enterprise currently valued at $1.09 billion, trades above its InvestingPro Fair Value metric. This positioning places the company on the platform's Most Overvalued list. Detailed analysis of OMDA is accessible through a comprehensive Pro Research Report, which is available for this equity and over 1,400 other US equities.
Recent financial disclosures for the first quarter of 2026 highlight key performance indicators for the company. Omada Health reported an earnings per share (EPS) of -$0.05, which surpassed the forecasted EPS of -$0.08. Revenue for the period reached $78 million, marking a 42% increase compared to the same period in the previous year.
Market analysis from Citizens indicates a revised outlook for the stock. The firm raised its price target for Omada Health to $21 from $18, while maintaining a Market Outperform rating. Analyst Constantine Davides noted that the company recently traded at 2.5 times the firm's 2026 revenue estimate.
Corporate governance updates include the completion of Omada Health's 2026 Annual Meeting of Stockholders. During this meeting, shareholders elected Sean Duffy and Trevor Fetter as Class I Directors. Both individuals are scheduled to serve until the 2029 annual meeting. These governance changes occur as Omada Health navigates its post-IPO phase, with the stock trading between 1.3 times and 6.6 times forward revenue since June 2025.